ONVO
Open
–
Prev. Close
–
High
–
Low
–
Organovo Holdings Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2013-08-02. Organovo Holdings, Inc. is a clinical-stage biotechnology company. The firm is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company focuses on developing novel treatment approaches in inflammatory bowel disease (IBD). The firm has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The company uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. Its Mosaic division to serve as a key source of certain primary human cells it utilizes in its research and development efforts. Its 3D human tissue platform is multifaceted. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters.
emptyResult
Organovo Holdings Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2013-08-02. Organovo Holdings, Inc. is a clinical-stage biotechnology company. The firm is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company focuses on developing novel treatment approaches in inflammatory bowel disease (IBD). The firm has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The company uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. Its Mosaic division to serve as a key source of certain primary human cells it utilizes in its research and development efforts. Its 3D human tissue platform is multifaceted. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters.